Kelun-Biotech Surges 3% on TROP2 ADC Phase 3 Success; HK Connect Innovative Drug ETF Rises Amid Clinical Breakthrough
May 19, 2026 10:46
CST Updated
11:11
Kelun-Biotech
Innovative Drug Developer
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
Innovent
High-end Biologics Developer